Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis

Grant Award Details

Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis

Grant Type: Late Stage Preclinical Projects

Grant Number: CLIN1-09472

Project Objective: File an IND with the US FDA by 3/31/2018

Investigator:

Name:	Jack Wang
Institution:	Cellular Biomedicine Group, Inc.
Type:	PI

Disease Focus: Bone or Cartilage Disease, Osteoarthritis

Human Stem Cell Use: Other

Cell Line Generation: Other

Award Value: $2,291,976

Status: Active

Grant Application Details

Application Title: Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis

Public Abstract:

Therapeutic Candidate or Device

Intra-articularly injected allogeneic culture-expanded human adipose derived mesenchymal progenitor cells

Indication

Knee osteoarthritis

Therapeutic Mechanism

Cartilage regeneration (as determined by cartilage volume increase), immunomodulatory effects

Unmet Medical Need

There is no approved disease modification therapy for osteoarthritis (OA), and OA is a leading cause of both hospitalization and joint replacement surgery. Our product provides symptom relief and structure modification benefits.

Project Objective

File IND

Major Proposed Activities

- Manufacture product to supply the proposed trial
- Complete non-clinical safety study requested by the FDA
- File IND

Statement of Benefit to California:

California spends more on osteoarthritis (OA) management than any other state in the union and financial and human cost of OA is expected to worsen with the upward trend in obesity and the ageing baby boomer generation. Our allogenic adipose-derived mesenchymal progenitor cells has the potential to reduce the need for total knee joint replacement, offer a viable regenerative treatment for OA, and significantly reduce healthcare costs in California. .

Source URL: https://www.cirm.ca.gov/our-progress/awards/allogenic-human-adipose-derived-mesenchymal-stem-cells-treatment-knee